Table 1.

GP prevents HFD-induced hyperlipidemia

	TC (mmol/L)	TG (mmol/L)	LDL-C (mmol/L)	HDL-C (mmol/L)
NAFLD	2.14 ± 0.26	0.63 ± 0.04	1.61 ± 0.10	0.32 ± 0.17
Control	1.26 ± 0.24**	0.50 ± 0.07**	1.26 ± 0.34*	0.47 ± 0.15**
DLPC	1.98 ± 0.62	0.51 ± 0.08*	1.15 ± 0.25**	0.47 ± 0.21*
GPL	1.87 ± 0.33	0.48 ± 0.07**	1.14 ± 0.21**	0.39 ± 0.12
GPM	1.69 ± 0.28*	0.48 ± 0.07**	1.16 ± 0.36**	0.51 ± 0.08**
GPH	1.29 ± 0.27**	0.49 ± 0.16**	1.14 ± 0.24**	0.54 ± 0.09**

Serum concentrations of TC, TG, LDL-C and HDL-C in each group compared with NAFLD group (n = 10 for each group). Data are shown as mean ± standard deviation. Whereas * and ** represent statistically significant results (P < 0.05, P < 0.01, respectively) based on Newman–Keuls post hoc one-way ANOVA analysis. GPL: low dose of GP treatment; GPM: middle dose of GP treatment; GPH: high dose of GP treatment